Research article summary (published 30 Mar 2008):

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

Full Abstract

INTRODUCTION: Recent clinical success of epidermal growth factor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) have raised hopes that targeting other deregulated growth factor signaling, such as the hepatocyte growth factor/MET pathway, will lead to new therapeutic options for NSCLC. Furthermore, NSCLC present secondary EGFR-TKIs resistance related to exons 20 and 19 EGFR mutations or more recently to MET amplification. The aim of this study was to determine MET copy number related to EGFR copy number and K-Ras mutations in a targeted TKI naive NSCLC cohort. METHODS: We investigated 106 frozen tumors from surgically resected NSCLC patients. Genes copy number of MET and EGFR were assessed by quantitative relative real-time polymerase chain reaction and K-Ras mutations by sequencing. RESULTS: MET is amplified in 22 cases (21%) and deleted in nine cases (8.5%). EGFR is amplified in 31 cases (29%). K-Ras is mutated in 11 cases (10.5%). As observed for EGFR amplification, MET amplification is never associated with K-Ras mutation. MET amplification could be associated with EGFR amplification. MET amplification is not related to clinical and pathologic features. MET amplification and EGFR amplification showed a trend toward poor prognosis in adenocarcinomas. CONCLUSION: In EGFR-TKIs naive NSCLC patients, MET amplification is a frequent event, which could be associated with EGFR amplification, but not with K-Ras mutation. MET amplification may identify a subset of NSCLC for new targeted therapy. It will also be important to evaluate MET copy number to properly interpret future clinical trials.

Author information

Author/s: Beau-Faller, Michèle (M); Ruppert, Anne-Marie (AM); Voegeli, Anne-Claire (AC); Neuville, Agnès (A); Meyer, Nicolas (N); Guerin, Eric (E); Legrain, Michèle (M); Mennecier, Bertrand (B); Wihlm, Jean-Marie (JM); Massard, Gilbert (G); Quoix, Elisabeth (E); Oudet, Pierre (P); Gaub, Marie P (MP);

Affiliation: Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg Cedex, France. michele.faller(-atsign-)chru-strasbourg.fr

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol), published in United States. (Language: eng)

Reference: 2008-Apr; vol 3 (issue 4) : pp 331-9

Dates: Created 2008/04/01; Completed 2008/05/27;

PMID: 18379349, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Adenocarcinoma - genetics; secondary; surgery Adenocarcinoma, Bronchiolo-Alveolar - genetics; secondary; surgery Adult Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - genetics; pathology; surgery Carcinoma, Squamous Cell - genetics; secondary; surgery Cohort Studies DNA Mutational Analysis Female Gene Dosage Humans

Humans Lung Neoplasms - genetics; pathology; surgery Male Middle Aged Prognosis Proto-Oncogene Proteins - genetics RNA, Messenger - genetics; metabolism Receptor, Epidermal Growth Factor - genetics Receptors, Growth Factor - genetics Reverse Transcriptase Polymerase Chain Reaction Survival Rate ras Proteins - genetics

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: KRAS protein, human (0) ; Proto-Oncogene Proteins (0) ; RNA, Messenger (0) ; Receptors, Growth Factor (0) ; MET protein, human (EC 2.7.1.112) ; Receptor, Epidermal Growth Factor (EC 2.7.1.112) ; ras Proteins (EC 3.6.5.2)

Related articles

These are the most related articles currently in our database:

• Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 13 May 2006
• Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. 27 Feb 2006
• Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. 30 Oct 2008
• EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 30 Jan 2005
• BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. 5 Nov 2007
• [A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation] 30 Aug 2008
• Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 29 Jun 2007
• K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients. 30 Dec 2007
• Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. 29 Jun 2005
• Microsatellite instability in female non-small-cell lung cancer patients with familial clustering of malignancy. 27 Feb 1998

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.